Deep segmentation networks predict survival of non-small cell lung cancer
Authors:
Stephen Baek,
Yusen He,
Bryan G. Allen,
John M. Buatti,
Brian J. Smith,
Ling Tong,
Zhiyu Sun,
Jia Wu,
Maximilian Diehn,
Billy W. Loo,
Kristin A. Plichta,
Steven N. Seyedin,
Maggie Gannon,
Katherine R. Cabel,
Yusung Kim,
Xiaodong Wu
Abstract:
Non-small-cell lung cancer (NSCLC) represents approximately 80-85% of lung cancer diagnoses and is the leading cause of cancer-related death worldwide. Recent studies indicate that image-based radiomics features from positron emission tomography-computed tomography (PET/CT) images have predictive power on NSCLC outcomes. To this end, easily calculated functional features such as the maximum and th…
▽ More
Non-small-cell lung cancer (NSCLC) represents approximately 80-85% of lung cancer diagnoses and is the leading cause of cancer-related death worldwide. Recent studies indicate that image-based radiomics features from positron emission tomography-computed tomography (PET/CT) images have predictive power on NSCLC outcomes. To this end, easily calculated functional features such as the maximum and the mean of standard uptake value (SUV) and total lesion glycolysis (TLG) are most commonly used for NSCLC prognostication, but their prognostic value remains controversial. Meanwhile, convolutional neural networks (CNN) are rapidly emerging as a new premise for cancer image analysis, with significantly enhanced predictive power compared to other hand-crafted radiomics features. Here we show that CNN trained to perform the tumor segmentation task, with no other information than physician contours, identify a rich set of survival-related image features with remarkable prognostic value. In a retrospective study on 96 NSCLC patients before stereotactic-body radiotherapy (SBRT), we found that the CNN segmentation algorithm (U-Net) trained for tumor segmentation in PET/CT images, contained features having strong correlation with 2- and 5-year overall and disease-specific survivals. The U-net algorithm has not seen any other clinical information (e.g. survival, age, smoking history) than the images and the corresponding tumor contours provided by physicians. Furthermore, through visualization of the U-Net, we also found convincing evidence that the regions of progression appear to match with the regions where the U-Net features identified patterns that predicted higher likelihood of death. We anticipate our findings will be a starting point for more sophisticated non-intrusive patient specific cancer prognosis determination.
△ Less
Submitted 8 November, 2019; v1 submitted 26 March, 2019;
originally announced March 2019.
Adding new experimental arms to randomised clinical trials: impact on error rates
Authors:
Babak Choodari-Oskooei,
Daniel J Bratton,
Melissa R Gannon,
Angela M Meade,
Matthew R Sydes,
Mahesh KB Parmar
Abstract:
Background: Experimental treatments pass through various stages of development. If a treatment passes through early phase experiments, the investigators may want to assess it in a late phase randomised controlled trial. An efficient way to do this is adding it as a new research arm to an ongoing trial. This allows to add the new treatment while the existing arms continue. The familywise type I err…
▽ More
Background: Experimental treatments pass through various stages of development. If a treatment passes through early phase experiments, the investigators may want to assess it in a late phase randomised controlled trial. An efficient way to do this is adding it as a new research arm to an ongoing trial. This allows to add the new treatment while the existing arms continue. The familywise type I error rate (FWER) is often a key quantity of interest in any multi-arm trial. We set out to clarify how it should be calculated when new arms are added to a trial some time after it has started.
Methods: We show how the FWER, any-pair and all-pairs powers can be calculated when a new arm is added to a platform trial. We extend the Dunnett probability and derive analytical formulae for the correlation between the test statistics of the existing pairwise comparison and that of the newly added arm. We also verify our analytical derivation via simulations.
Results: Our results indicate that the FWER depends on the shared control arm information (i.e. individuals in continuous and binary outcomes and primary outcome events in time-to-event outcomes) from the common control arm patients and the allocation ratio. The FWER is driven more by the number of pairwise comparisons and the corresponding (pairwise) Type I error rates than by the timing of the addition of the new arms. The FWER can be estimated using Šidák's correction if the correlation between the test statistics of pairwise comparisons is less than 0:30.
Conclusions: The findings we present in this article can be used to design trials with pre-planned deferred arms or to design new pairwise comparisons within an ongoing platform trial where control of the pairwise error rate (PWER) or FWER (for a subset of pairwise comparisons) is required.
△ Less
Submitted 14 February, 2019;
originally announced February 2019.
Random walks in a queueing network environment
Authors:
M. Gannon,
E. Pechersky,
Y. Suhov,
A. Yambartsev
Abstract:
We propose a class of models of random walks in a random environment where an exact solution can be given for a stationary distribution. The tool is the detailed balance equations.
We propose a class of models of random walks in a random environment where an exact solution can be given for a stationary distribution. The tool is the detailed balance equations.
△ Less
Submitted 26 May, 2015; v1 submitted 6 October, 2014;
originally announced October 2014.
